Gene-based therapy in prostate cancer

Lancet Oncology

Volumn 5, Issue 8, 2004, Pages 469-479

  Foley, Ruth ^a   Lawler, Mark ^a   Hollywood, Donal ^a,b  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CASPASE 9; CYTOKINE; CYTOSINE DEAMINASE; DIPHTHERIA TOXIN; DOCETAXEL; DOUBLE STRANDED DNA; FLUCYTOSINE; GAMMA GLUTAMYL HYDROLASE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; KALLIKREIN; MUTANT PROTEIN; OLIGONUCLEOTIDE; PROBASIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; THROMBOSPONDIN 1; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VALACICLOVIR;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CAUSE OF DEATH; CLINICAL TRIAL; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; LYMPHOCYTOPENIA; MORBIDITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; TISSUE SPECIFICITY; VIRAL GENE DELIVERY SYSTEM; GENE TRANSFER; GENETICS; MALE; PROSTATE TUMOR;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MALE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS;

EID: 4043082727     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01525-6     Document Type: Review

References (75)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture Eur J Cancer 37 suppl 2001 S4-S66
2. Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer Cancer Res 62 2002 4427-4433
3. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822-826
4. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial Hum Gene Ther 10 1999 1239-1249
5. Yoshimura I, Ikegami S, Suzuki S, et al. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system J Urol 168 2002 2659-2664
6. Huber BE, Austin EA, Good SS, et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase Cancer Res 53 1993 4619-4626
7. Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy Hum Gene Ther 12 2001 1955-1967
8. Teh BS, Aguilar-Cordova E, Kernen K, et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report Int J Radiat Oncol Biol Phys 51 2001 605-613
9. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res 62 2002 4968-4976
10. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer Hum Gene Ther 14 2003 227-241
11. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate to high-risk prostate cancer Cancer Res 63 2003 7497-7506
12. Asgari K, Sesterhenn IA, McLeod DG, et al. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector Int J Cancer 71 1997 377-382
13. Li X, Marani M, Yu.J, et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer Cancer Res 61 2001 186-191
14. Xie X, Zhao X, Liu Y, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer Cancer Res 61 2001 6795-6804
15. Peng W, Verbitsky A, Bao Y, Sawicki J. Regulated expression of diphtheria toxin in prostate cancer cells Mol Ther 6 2002 537-545
16. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res 61 2001 7464-7472
17. Jin RJ, Kwak C, Lee SG, et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts Cancer Gene Ther 7 2000 1537-1542
18. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer Urology 53 1999 260-266
19. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology Hum Gene Ther 12 2001 883-892
20. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 1999 5160-5168
21. Shah AH Tabayoyong WB Kundu SD et al. Suppression of tumor metastasis by blockade of transforming growth factor beta signalling in bone marrow cells through a retroviral-mediated gene therapy in mice Cancer Res 62 2002 7135-7138
22. Kuratsukuri K Sugimura K Harimoto K et al. Decoy of androgen-responsive element induces apoptosis in LNCaP cells Prostate 41 1999 121-126
23. Eder IE Hoffmann J Rogatsch H et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor Cancer Gene Ther 9 2002 117-125
24. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer Semin Oncol 28 suppl 2001 67-70
25. Steiner MS Anthony CT Lu Y Holt JT. Antisense c-myc retroviral vector suppresses established human prostate cancer Hum Gene Ther 9 1998 747-755
26. Shi Y. Mammalian RNAi for the masses Trends Genet 19 2003 9-12
27. Varambally S Dhanasekaran SM Zhou M et al.The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624-629
28. Carbone GM McGuffie EM Collier A Catapano CV. Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide Nucleic Acids Res 31 2003 833-843
29. Bonnet MC Tartaglia J Verdier F et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers Immunol Lett 74 2000 11-25
30. Nishikawa M Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy Biol Pharm Bull 25 2002 275-283
31. Pawelek JM Low KB Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector Cancer Res 57 1997 4537-4544
32. Cunningham C.Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Hum Gene Ther 2001; 12: 1594-1596 (abstr)
33. Hacein-Bey-Abina S Von Kalle C Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302 2003 415-419
34. Zheng JY Chen D Chan J et al. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A Cancer Gene Ther 10 2003 764-770
35. Steiner MS, Lerner J, Greenberg, M et al. Clinical phase I gene therapy trial using BRCA1 retrovirus is safe. J Urol 1998; 159: 132 (abstr)
36. Barbour V. The balance of risk and benefit in gene-therapy trials Lancet 355 2000 384
37. The Lancet Gene therapy under cloud Lancet 355 2000 329
38. Chen HH Mack LM Kelly R et al. Persistence in muscle of an adenoviral vector that lacks all viral genes Proc Natl Acad Sci USA 94 1997 1645-1650
39. Trudel S Trachtenberg J Toi A et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer Cancer Gene Ther 10 2003 755-763
40. Gnant MF Noll LA Irvine KR et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases J Natl Cancer Inst 91 1999 1744-1750
41. Eder JP Kantoff PW Roper K et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer Clin Cancer Res 6 2000 1632-1638
42. Gulley J Chen AP Dahut W et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer Prostate 53 2002 109-117
43. Nakai H Iwaki Y Kay MA Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver J Virol 73 1999 5438-5447
44. Palmer JA Branston RH Lilley CE. et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system J Virol 74 2000 5604-5618
45. Lilley CE Groutsi F Han Z et al. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo J Virol 75 2001 4343-4356
46. Ishida T Kirchmeier MJ Moase EH. et al. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells Biochim Biophys Acta 1515 2001 144-158
47. Shi F Nomden A Oberle V et al. Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: down-regulation of the corticotropin-releasing factor receptor Nucleic Acids Res 29 2001 2079-2087
48. Otomo T Yamamoto S Morishita R Kaneda Y. EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy J Gene Med 3 2001 345-352
49. Meyer O Kirpotin D Hong K et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides J Biol Chem 273 1998 15621-15627
50. Frønsdal K Engedal N Slagsvold T Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1 J Biol Chem 273 1998 31853-31859
51. Mikata K Uemura H Ohuchi H et al. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation Mol Cancer Ther 1 2002 247-252
52. Kim JJ Trivedi NN Wilson DM et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine Oncogene 17 1998 3125-3135
53. Meía JE Willmott A Levy E et al. Functional complementation of a genetic deficiency with human artificial chromosomes Am J Hum Genet 69 2001 315-326
54. Iyer M Wu L Carey M et al. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters Proc Natl Acad Sci USA 98 2001 14595-14600
55. Wu L Matherly J Smallwood A et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors Gene Ther 8 2001 1416-1426
56. Steiner MS Zhang Y Carraher J Lu Y. In vivo expression of prostate-specific adenoviral vectors in a canine model Cancer Gene Ther 6 1999 456-464
57. Wu X Wu J Huang J et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation Mech Dev 101 2001 61-69
58. McDonnell TJ Troncoso P Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940-6944
59. Small EJ Roach 3rd. M. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response Semin Oncol 29 2002 264-273
60. Rodriguez R Schuur ER Lim HY et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 57 1997 2559 2563
61. Wei C Willis RA Tilton BR et al. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy Proc Natl Acad Sci USA 94 1997 6369-6374
62. Bright RK Vocke CD Emmert-Buck MR et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens Cancer Res 57 1997 995-1002
63. Spitzweg C O'Connor MK Bergert ER et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter Cancer Res 60 2000 6526-6530
64. Sweat SD Pacelli A Murphy GP Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 1998 637-640
65. Wright GL Jr Grob BM Haley C et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 1996 326-334
66. Uchida A O'Keefe DS Bacich DJ et al. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy Urology 58 suppl 2001 132-139
67. Good D Schwarzenberger P Eastham JA et al. Cloning and characterization of the prostate-specific membrane antigen promoter J Cell Biochem 74 1999 395-405
68. Matsubara S Wada Y Gardner TA et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis Cancer Res 61 2001 6012-6019
69. Foley R, Molloy K, Hollywood D, Lawler M. Suicide gene therapy approaches for prostate cancer: potential synergy with radiotherapy. Cancer Gene Ther 2000 7 (suppl) S21-S22 (abstr)
70. Majumdar S Diamandis EP. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines Br J Cancer 79 1999 1594-1602
71. Lee SJ Kim HS Yu R et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers Mol Ther 6 2002 415-421
72. Freytag SO Paielli D Wing M et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model Int J Radiat Oncol Biol Phys 54 2002 873-885
73. Yang C Cirielli C Capogrossi MC Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells Cancer Res 55 1995 4210-4213
74. Eastham JA Hall SJ Sehgal I et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer Cancer Res 55 1995 5151-5155
75. Nakanishi H Mazda O Satoh E et al. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo Gene Ther 10 2003 434-442